K. Byth

发表

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

S. Fox, K. Byth, S. Lade, 2018, Nature Communications.

Mechanism and in vitro pharmacology of TAK1 inhibition by (5Z)-7-Oxozeaenol.

Jon Read, Zhongwu Lai, Francoise Powell, 2013, ACS chemical biology.

Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma

S. Grosskurth, B. Davies, Scott A. Ezell, 2016, Oncotarget.

AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis

Rajesh Odedra, Stephen Green, John R. Foster, 2007, Clinical Cancer Research.

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity

M. Firth, Paul D. Smith, Kate F. Byth, 2017, Oncotarget.

Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors.

J. Breed, D. M. Andrews, A. Barker, 2008, Bioorganic & medicinal chemistry letters.

AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts

A. Barker, Kate F. Byth, Catherine Geh, 2009, Molecular Cancer Therapeutics.

Towards the next generation of dual Bcl-2/Bcl-xL inhibitors.

Kate F. Byth, Prasenjit Mukherjee, J. Saeh, 2014, Bioorganic & medicinal chemistry letters.

Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6.

David M. Wilson, Qing Cao, M. Waring, 2018, ACS chemical biology.

Essential role of TAK1 in regulating mantle cell lymphoma survival.

A. Younes, Kate F. Byth, D. Buglio, 2012, Blood.

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

S. Fox, S. Lade, N. Traficante, 2018, Nature Communications.

Comparative analysis of primary versus relapse/refractory DLBCL identifies shifts in mutation spectrum

Rebecca F. Halperin, Winnie S. Liang, J. Carpten, 2017, Oncotarget.

Discovery of heterocyclic sulfonamides as sphingosine 1-phosphate receptor 1 (S1P1) antagonists.

E. Hennessy, L. Ronco, V. Oza, 2015, Bioorganic & medicinal chemistry letters.

Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity.

E. Hennessy, V. Oza, P. Lyne, 2015, Journal of medicinal chemistry.

AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

Tristan J. Lubinski, E. Hennessy, M. Garnett, 2020, Clinical Cancer Research.

Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma

S. Grosskurth, C. Reimer, Scott A. Ezell, 2014, Oncotarget.

Imidazo[1,2-a]pyridines. Part 2: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors.

Kate F. Byth, Sandra E. Oakes, Andrew P Thomas, 2004, Bioorganic & medicinal chemistry letters.

Imidazo[1,2-a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation.

J. Breed, R. Pauptit, C. Minshull, 2003, Bioorganic & medicinal chemistry letters.

Development of a novel BCL6 PROTAC to provide insight into small molecule targeting of BCL6

David M. Wilson, Qing Cao, M. Waring, 2018 .

AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.

G. Shapiro, D. Cai, Kate F. Byth, 2006, Cancer research.

Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors.

Matthew Grist, C. Chuaqui, Qing Cao, 2017, Journal of medicinal chemistry.

The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis

E. Latz, J. Trebicka, Kate F. Byth, 2021, Frontiers in Molecular Biosciences.

Novel approaches in oncology at AstraZeneca

S. Wedge, D. Blakey, Kate F. Byth, 2003 .

AZD 5438 , a potent oral inhibitor of cyclin-dependent kinases 1 , 2 , and 9 , leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts

A. Barker, Kate F. Byth, Catherine Geh, 2009 .

A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers

D. Camidge, Kate F. Byth, C. Forder, 2007, Cancer Chemotherapy and Pharmacology.

The cellular phenotype of AZ703, a novel selective imidazo[1,2-a]pyridine cyclin-dependent kinase inhibitor

Kate F. Byth, Catherine Geh, C. Forder, 2006, Molecular Cancer Therapeutics.

Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors.

D. M. Andrews, A. Barker, Kate F. Byth, 2008, Bioorganic & medicinal chemistry letters.